Climate Change Data

Environmental Metrics

ESG Focus Areas

• Access to healthcare
• Environmental protection
• Ethics and transparency

Environmental Achievements

• 60% reduction in Scope 1 and 2 greenhouse gas emissions since 2015
• 2% reduction in waste since 2015
• 20% reduction in water use since 2015
• 100% of API discharges from AstraZeneca sites assessed as safe and 94% from suppliers

Social Achievements

• Launched Take CaRe of Me programme to promote early awareness of type 2 diabetes complications
• Committed to diversity in clinical trials
• Launched Partnership for Health System Sustainability and Resilience with LSE and WEF
• Entered into over 100 value-based agreements
• Ranked 7th out of 20 companies in the Access to Medicines Index (ATMI)
• 84% of employee survey respondents feel that AstraZeneca has a ‘Speak Up’ culture
• 89% of employee survey respondents feel that AstraZeneca is a Great Place to Work
• 46.9% women in senior middle management roles and above
• Launched supplier diversity programmes in two new countries

Governance Achievements

• Published artificial intelligence ethics principles and governance
• 49.1 instances of non-compliance with the Code of Ethics per thousand employees in commercial business units

Climate Goals & Targets

Environmental Challenges

• Challenges in 2020 for patients accessing treatment for NCDs due to the pandemic
• Reputational risks and opportunities based upon the quality of our response to public health emergencies such as the COVID-19 pandemic
• Pandemic impact on initiation, ongoing recruitment and follow-up in some clinical trials
• Global dialogue and action to combat the climate crisis
• Global risks are acutely felt, and local risks can quickly go global
• Health disparities exist in all healthcare systems
• Challenges that some markets face with regards to their healthcare gaps
• Category of 'Pricing, affordability, access and competitive pressures' is an AstraZeneca principal risk
• Increasing regulatory pressures including proposals from the European Parliament and the OECD to include environmental hazard and risk within the approval of new medicinal products
• Continued presence of drug residues in a range of drinking, surface and ground waters as well as soils and sediments
• Water scarcity has the potential to cause temporary site shut-downs
• Climate change projections indicate that these risks will grow in the coming years
• Achieving our total 10% waste reduction target will be a challenge
• Many barriers to realising circularity
• Lack of public trust in big corporations
• Scepticism is even greater towards companies in the pharmaceutical industry
• Some risk of ineffectively addressing Ethical business culture
• Scientific and technological developments continue to gather pace
• Some risk of ineffectively addressing Inclusion and diversity
• Aspects of Talent and workforce evolution are captured in our enterprise risk management process
• Some Workforce wellbeing and safety risks are included in the risk 'Failure to adhere to applicable laws, rules and regulations'
• Aspects of Responsible supply chain are implicated in at least three areas of our enterprise risk management process
• Aspects of Human rights are implicated in our risk 'Failure to adhere to applicable laws, rules and regulations'

Mitigation Strategies

• Redesigned clinical trials to avoid disruption
• Pledged financial commitments to patient advocacy groups
• Monitored more than 1,300 global logistics routes
• Launched a secure digital platform for employees
• Additional health and safety measures were put in place
• Provided support and guidance to employees with suspected or confirmed COVID-19
• Updated our Global Volunteering Policy
• Provided more than $15 million in COVID-19 donations
• Conducted environmental risk assessments
• Co-authored a 10-point action plan to create a circular bioeconomy
• Recovered heat from mask incineration
• Launched The Partnership for Health System Sustainability and Resilience (PHSSR)
• Adjusted our programmes to meet local needs related to COVID-19
• Applied value-based agreements (VBA)
• Worked closely with healthcare systems, payers and policymakers
• Offered access and affordability programmes to patients
• Donated medicines through non-profit partners
• Entered into over 100 innovative value-based agreement partnerships
• Developed and piloted an internal Product Sustainability Index (PSI)
• Launched Ambition Zero Carbon
• Gaining transparency on Scope 3 emissions
• Increased procurement of renewable imported electricity
• Joined the Renewable Thermal Collaborative
• Strengthened commitments under the Climate Group's EP100 and EV100 initiatives
• Prioritised creation of Ambition Zero Carbon roadmaps for our 10 key sites
• Integrated climate risks into the overall risk management process
• Launched a new ethics case management platform
• Updated our Information Incident Form
• Introduced an automated routing and notification process
• Enhanced the 2020 survey with terminology definitions
• Increased paid maternity leave
• Participated in a Pharmaceutical Supply Chain Initiative (PSCI) project
• Conducted 1,884 PIAs
• Provided training that aligns our day-to-day practices with our 'Speak Up' culture
• Offered wellbeing guidance resources
• Provided flexible working options
• Launched employee assistance programmes
• Deployed manager training
• Integrated HOP into our business
• Adjusted the site process in Coppell
• Started a serious injury or fatality (SIF) prevention programme in our warehouses
• Enhanced our third-party expectations and request for proposal (RFP) guidance
• Launched a new Operations Sustainability Council
• Embedded sustainability in both our product and supply chain design approach
• Began to build a framework to drive change for materials of natural origin
• Increased paid maternity leave

Supply Chain Management

Supplier Audits: 75 safe API discharge supplier assessments completed

Responsible Procurement

• Global Standard Expectations of Third Parties
• Sustainability Partner Guide and Framework
• Positive Sourcing Programme

Climate-Related Risks & Opportunities

Physical Risks

• Floods
• Water scarcity
• Extreme heat
• Cyclones
• Wildfires

Transition Risks

• Climate-focused environmental policy and regulation
• Kigali Amendment to the Montreal Protocol
• US and EU F-Gas review

Opportunities

• Development of energy-efficient products
• Transition to next-generation respiratory inhalers with near zero climate impact
• Explore how to ‘design in’ carbon neutrality across our organisation
• Engage with our suppliers to reduce emissions

Reporting Standards

Frameworks Used: GRI, TCFD, UNGC

Certifications: ISO 14001, ISO 45001, ISO 50001

Third-party Assurance: Bureau Veritas

UN Sustainable Development Goals

• SDG 3
• SDG 5
• SDG 8
• SDG 12
• SDG 13
• SDG 17
• SDG 6
• SDG 15

The six goals and 12 targets that resulted from this prioritisation represent where AstraZeneca has the greatest capacity for impact and action.

Sustainable Products & Innovation

• Next-generation inhalers with near zero climate impact
• Innovative DxTx aimed at supporting earlier identification and management of Interstitial Lung Disease (ILD)

Awards & Recognition

• CDP Climate Change A list (five consecutive years)
• CDP Water Security A list (five consecutive years)
• Bloomberg Gender Equality Index
• 2020 Diversity List by Diversity Inc
• Corporate Equality Index
• Mexico Equity certification from the Human Rights Campaign Foundation
• Workforce Disclosure Initiative
• Top Organisation Award for the 2020 Freezer Challenge
• Silver award for The Healthiest Maryland Businesses (HMB) Wellness at Work awards programme
• The Alliance for Workplace Excellence Health & Wellness Seal of Approval
• 2020 HubZone Prime Contractor National Award
• 2020 Corporate Done Deal Award
• 2020 Corporate Champion Award